For the three months ended July 3, the Washington DC-based conglomerate recorded $5.30 billion in total sales compared to $4.44 billion in the year-ago period.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.
While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
Developed using the center's "industrialized" proteomics workflow, the panel identified patients up to a year before their diagnosis with 89 percent accuracy.
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
At the recent ASMS annual meeting, vendors including Bruker, Sciex, and Thermo Fisher Scientific presented new versions of the fast-growing mass spec technique.
